Dietrich EA - Search Results

1

Comparative effectiveness of sacubitril/valsartan versus angiotensin receptor blockers in patients with heart failure with preserved ejection fraction: A real-world study.

Riaz M, Smith SM, Dietrich EA, Winchester DE, Guo J, Park H. Riaz M, et al. Among authors: dietrich ea. Am J Health Syst Pharm. 2024 Jul 8;81(14):599-607. doi: 10.1093/ajhp/zxae053. Am J Health Syst Pharm. 2024. PMID: 38427969

2

Feasibility of Extended-interval Follow-up for Patients Receiving Warfarin.

Carris NW, Spinelli A, Pierini D, Taylor JR, Anderson KV, Sando K, Powell J, Rosenberg EI, Zumberg MS, Smith SM, Gums JG, Dietrich E. Carris NW, et al. Cardiovasc Ther. 2015 Jun;33(3):98-103. doi: 10.1111/1755-5922.12115. Cardiovasc Ther. 2015. PMID: 25786578 Free article. Clinical Trial.

3

Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension.

Smith SM, Carris NW, Dietrich E, Gums JG, Uribe L, Coffey CS, Gums TH, Carter BL. Smith SM, et al. J Am Soc Hypertens. 2016 Apr;10(4):307-17. doi: 10.1016/j.jash.2016.01.010. Epub 2016 Jan 18. J Am Soc Hypertens. 2016. PMID: 26852290 Free PMC article. Clinical Trial.

4

Patient satisfaction with extended-interval warfarin monitoring.

Carris NW, Hwang AY, Smith SM, Taylor JR, Sando K, Powell J, Rosenberg EI, Zumberg MS, Gums JG, Dietrich EA, Anderson KV. Carris NW, et al. Among authors: dietrich ea. J Thromb Thrombolysis. 2016 Nov;42(4):486-93. doi: 10.1007/s11239-016-1385-9. J Thromb Thrombolysis. 2016. PMID: 27251646 Clinical Trial.

5

Resistant Hypertension: Mechanisms and Treatment.

Hwang AY, Dietrich E, Pepine CJ, Smith SM. Hwang AY, et al. Curr Hypertens Rep. 2017 Jul;19(7):56. doi: 10.1007/s11906-017-0754-x. Curr Hypertens Rep. 2017. PMID: 28597403 Review.

6

Evaluation of SAMe-TT₂R₂ Score on Predicting Success With Extended-Interval Warfarin Monitoring.

Hwang AY, Carris NW, Dietrich EA, Gums JG, Smith SM. Hwang AY, et al. Among authors: dietrich ea. Ann Pharmacother. 2018 Nov;52(11):1085-1090. doi: 10.1177/1060028018779774. Epub 2018 Jun 1. Ann Pharmacother. 2018. PMID: 29857777

7

Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.

Dawwas GK, Brown J, Dietrich E, Park H. Dawwas GK, et al. Lancet Haematol. 2019 Jan;6(1):e20-e28. doi: 10.1016/S2352-3026(18)30191-1. Epub 2018 Dec 14. Lancet Haematol. 2019. PMID: 30558988

8

Can apixaban prevent venous thromboembolism better than rivaroxaban? - Authors' reply.

Dawwas GK, Brown J, Dietrich E, Park H. Dawwas GK, et al. Lancet Haematol. 2019 Apr;6(4):e181-e182. doi: 10.1016/S2352-3026(19)30049-3. Lancet Haematol. 2019. PMID: 30926080 No abstract available.

9

Reimbursement of ambulatory blood pressure monitoring in the US commercial insurance marketplace.

Dietrich E, Desai R, Garg M, Park H, Smith SM. Dietrich E, et al. J Clin Hypertens (Greenwich). 2020 Jan;22(1):6-15. doi: 10.1111/jch.13772. Epub 2019 Dec 24. J Clin Hypertens (Greenwich). 2020. PMID: 31873973 Free PMC article.

10

Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.

Dawwas GK, Smith SM, Dietrich E, Lo-Ciganic WH, Park H. Dawwas GK, et al. Am J Health Syst Pharm. 2020 Jan 24;77(3):188-195. doi: 10.1093/ajhp/zxz307. Am J Health Syst Pharm. 2020. PMID: 31974557

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

84 results

Search Page

Filters